CytomX Therapeutics (CTMX) Asset Utilization Ratio (2015 - 2026)

CytomX Therapeutics has reported Asset Utilization Ratio for 12 years, with the latest figure at 0.14 in Q1 2026.

• For the quarter ending Q1 2026, Asset Utilization Ratio fell 89.67% year-over-year to 0.14; the trailing twelve-month figure through Mar 2026 stood at 0.14 (down 89.67% YoY), and the FY2025 full-year result was 0.56, down 34.64% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.14, down from 0.49 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 1.35 in Q1 2025, with the low at 0.12 in Q1 2022.
• Historically, Asset Utilization Ratio has averaged 0.54 across 5 years, with a median of 0.48 in 2023.
• Annual changes were most pronounced in 2023 — Asset Utilization Ratio surged 142.48% — and 2026, when it slumped 89.67%.
• CytomX Therapeutics' Asset Utilization Ratio stood at 0.22 in 2022, then jumped by 119.38% to 0.48 in 2023, then surged by 122.38% to 1.06 in 2024, then plunged by 53.78% to 0.49 in 2025, then plunged by 71.72% to 0.14 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.14 (Q1 2026), 0.49 (Q4 2025), and 0.68 (Q3 2025), per Business Quant data.